Since their introduction 20 years ago, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolu­tionised the treatment of diabetes and obesity. Known for their immunomodulatory and ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of type 2 diabetes and obesity. However, for many users, the benefits of weight loss and blood sugar management come ...

A research team led by the Department of Medicine, under the School of Clinical Medicine, LKS Faculty of Medicine of the ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

Lexaria Bioscience Corporation (NASDAQ:LEXX) announced results from its Phase Ib study evaluating multiple GLP-1 agonists in combination with DehydraTECH (DHT). The study met its primary endpoint with ...

Treatment with glucagon like peptide 1 receptor agonist (GLP-1 RA) medications was associated with a lower risk of being diagnosed with hidradenitis suppurativa (HS) or psoriasis, in a study of ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, ...

Research has suggested that GLP-1 receptor agonists may have protective effects against certain eye conditions, but they have also been linked to rare ophthalmic complications. In this retrospective ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. GLP-1 receptor agonists have protective effects in ...